PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
41.89
+0.04 (+0.10%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close41.85
Open41.81
Bid0.00 x 900
Ask0.00 x 800
Day's Range41.67 - 42.15
52 Week Range34.37 - 46.47
Volume18,808,072
Avg. Volume25,795,770
Market Cap232.565B
Beta (3Y Monthly)0.51
PE Ratio (TTM)22.45
EPS (TTM)1.87
Earnings DateApr 30, 2019
Forward Dividend & Yield1.44 (3.44%)
Ex-Dividend Date2019-01-31
1y Target Est44.14
Trade prices are not sourced from all markets
  • Were Hedge Funds Right About Pfizer Inc. (PFE)?
    Insider Monkey10 hours ago

    Were Hedge Funds Right About Pfizer Inc. (PFE)?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
    Zacks13 hours ago

    Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

    Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

  • PR Newswire17 hours ago

    S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

    - Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion - This is the fourth consecutive quarterly record -- longest streak in the 20 years SPDJI has tracked - Total 2018 buybacks ...

  • Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
    Zacks4 days ago

    Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

    Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

  • Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
    Zacks4 days ago

    Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order

    The index traversed yet another volatile week but still managed to notch up strong gains.

  • ETF.com5 days ago

    Boeing's Lesson About The Dow

    Not all U.S. equity indexes are created equal, and Boeing’s recent troubles are a good reminder of that.

  • Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
    Zacks5 days ago

    Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

    Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

  • Pfizer buys stake in French gene company in deal worth up to $636M
    American City Business Journals5 days ago

    Pfizer buys stake in French gene company in deal worth up to $636M

    Pfizer Inc. said it's buying a stake in a French gene company in a deal that could be worth up to $636 million. The New York drug company (NYSE: PFE) said it's paying $51 million upfront to acquire a 15 percent stake in Vivet Therapeutics of Paris. Vivet is working on a drug — VTX-801 — to treat Wilson disease, which is a rare and possibly fatal condition in which excess copper collects in the body's liver and other organs, perhaps to life-threatening levels.

  • InvestorPlace6 days ago

    Invest in America’s Rising Healthcare Costs With These Stocks

    Not a day goes by that healthcare costs aren't being discussed across each corner of media. With the 2020 election now underway, politicos are ratcheting up the rhetoric over healthcare costs and the political ads are already spinning the topic. And all of this is for good reason. Healthcare costs in the U.S. are high and rapidly rising, especially if you're of retirement age. According to the U.S. Centers for Medicare and Medicaid Services (CMS) -- healthcare spending increased in 2017 by 3.90% to $3.9 trillion or $10,739 per person. This represents 17.90% of the then gross domestic product of the U.S. (GDP). In fact, in a recently published book, More than Medicine: The Broken Promise of American Health by Bob Kaplan, he argues that the U.S. pays way more than its mature economic peers.For example, the U.S. pays 18% of its gross domestic product (GDP) on healthcare whereas the European Union (E.U.) only pays 10% of its combined GDP. And, to make it worse, the U.S. has a lower life expectancy than many nations around the globe. Add in a high poverty rate, which can lead to further health challenges for young and old and other factors showing health troubles, including infant mortality, and the nation doesn't look too healthy. American healthcare may well get even more expensive, as the U.S. ages and becomes less healthy by the day. This isn't a good mix for one of the leading economies of the planet.In a recent study by the U.S. Department of Commerce and the U.S. Census, by 2035, it is projected that 78 million folks will be 65 years or older. That same year, those at or under the age of 18 years will number just 76 million. America is becoming a nation of the elderly -- a significant change in the demographics of a nation traditionally known for its healthy and able folks. It's a shift that leaves many wondering where our economic productivity gains will come from. And, as we know, the elderly population requires the most attentive healthcare … no wonder healthcare spending is climbing.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks on the Rise Heading Into the Second Quarter While this sounds bleak, there is a silver lining here for us as investors. And no, I'm not suggesting that we look at gym companies (although I am poking around at that market with some innovations that I'll be writing about in Profitable Investing in the near future). Rather, I'm suggesting that investing in healthcare stocks that pay dividends is a smart source for capital gains … WP Carey Click to Enlarge Source: Bloomberg One healthcare stock, in particular, comes to mind … I'm referring to WP Carey (NYSE:WPC), which I've written about extensively for InvestorPlace.WP Carey is a REIT, which since coming to the public market, has generated a return of 1,348.28% for an average annual equivalent return of 13.46%. That's not too shabby any way you cut it. The business itself is a curious one: WP Carey doesn't operate its properties, and it doesn't pay for maintenance, insurance, or taxes. Instead, it executes "triple net leases." This means that it locks up long-term cashflows with less risk in rising costs for the properties and the vagrancies of tax rates.Its tenants pay for all of that, thus WP Carey profits from other peoples' money.In the healthcare market, there is a specific equivalent in the following security. Well, this next security is technically a real estate investment trust (REIT) that owns and acquires healthcare facilities including inpatient and outpatient facilities as well as surgical centers and specialty healthcare facilities. Their properties amount to more than 120 properties in 25 states as well as some newer innovative investments in Germany. Scroll down to discover what it is … Medical Properties Trust (MPW) Click to Enlarge Source: Bloomberg Medical Properties Trust (NYSE:MPW) has properties that are leased on a net basis to operators that run the facilities and pay rent month after month for years. The portfolio has expanded dramatically over the recent year with only a small pause in the past year. But it continues to look to expand its portfolio with the right properties in an ever-expanding market.Revenues are climbing with gains running at over 11.30% in just the trailing year. And the funds from operations (FFO) which measures just the return rate from the cashflows from the property portfolio is ample at 11.60%, which is impressive for the REIT space. This contributes to an impressive return on its assets at 11.40% and is what delivers for shareholders with a return on equity of 24.30%.And the stock continues to reflect its performance as a company. Over the past ten years, the stock has delivered a total return of 994.12% for an average annual equivalent of 26.79%. It is a disciplined company when it comes to debt and leverage as its debt to capital is at only 47.00%. This provides the ability to easily service its current debts and provides eased access for credit to fund additional acquisitions. Valued at only 1.49 times its book value, MPW is a steal from a price-book (P/B) perspective. This ratio has climbed significantly over the trailing year, from 1.14 times back in October 2018.But it isn't just the P/B ratio that's rising, but the actual value of the assets. Over the past five years alone, the underlying book value per share has gone from $7.98 to a current $12.27, which represents an impressive gain of 53.76%. This is important as it shows genuine growth in the underlying company and not just the stock price. The dividend is currently at 25 cents per share and has been climbing in distribution by an average annual rate of 4.30% over the past five years. This equates to a current yield of 5.48%. * Top 7 Service Sector Stocks That Will Pay You to Own Them Medical Properties Trust makes for a great buy in the healthcare market (which should be purchased in a taxable account). This is due to the Tax Cuts and Jobs Act (TCJA) which provides a tax deduction of 20% of the dividend distribution for U.S. individual investors making the taxable equivalent yield even higher. Other Stocks to Play HealthcareInside the Profitable Investing model portfolios, I have the overall market for healthcare synthetically invested in the Vanguard Healthcare ETF (NYSEARCA:VHT), which remains a buy in a tax-free account. Then, in my Incredible Dividend Machine portfolio inside Profitable Investing, I have three more plays on healthcare …I have the drugmaker Merck (NYSE:MRK), which continues to perform for shareholders. And I have another drugmaker in Pfizer (NYSE:PFE), which follows the success of Merck. Further, I also have Ventas (NYSE:VTR), which as a real estate investment trust (REIT) that owns a series of senior healthcare and related housing care facilities. VTR is doing quite well with the general REIT sector as we move further into 2019.One of the smartest investment lessons that I learned, from one of my best stocks within Profitable Investing, is to capitalize when the opportunity arises. That is, take risks while you lock in revenues! And the aforementioned stocks should continue to position themselves into the thick of the rising healthcare spending market while paying out an ample and rising dividend.Neil George is the editor of Profitable Investing and does not have any holdings in the securities mentioned above. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Invest in America's Rising Healthcare Costs With These Stocks appeared first on InvestorPlace.

  • Pfizer buys stake in French gene therapy firm Vivet
    Reuters6 days ago

    Pfizer buys stake in French gene therapy firm Vivet

    Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company. Pfizer already has collaboration agreements with gene therapy companies including Spark Therapeutics and Sangamo Therapeutics to target conditions like hemophilia and certain neurodegenerative disorders.

  • Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
    Zacks6 days ago

    Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

    Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.

  • Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
    Zacks6 days ago

    Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

    Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

  • Glaxo Presents Encouraging Data on Endometrial Cancer Drug
    Zacks6 days ago

    Glaxo Presents Encouraging Data on Endometrial Cancer Drug

    Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.

  • TheStreet.com6 days ago

    Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

    were falling slightly in trading after the drugmaker announced it has agreed to pay up to $636 million for the rights to a portfolio of gene therapies under development at French company Vivet Therapeutics. Pfizer acquired a 15% equity interest in Vivet up front for $51 million and secured an exclusive option to acquire all of the private company's outstanding shares. The two companies will collaborate on Vivet's propriety treatment for the chronic, life-threatening liver disorder Wilson disease.

  • The Wall Street Journal6 days ago

    Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak

    Inc. has agreed to pay up to €560 million ($636 million) for the rights to gene therapies under development at French company Vivet Therapeutics, as it seeks to build its pipeline in this cutting-edge treatment. The U.S. drugmaker said Wednesday it had paid €45 million upfront for a 15% stake in Vivet. Further payments, which include the potential acquisition of Vivet, are dependent on the progress of the French company’s experimental therapies.

  • Benzinga6 days ago

    The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • MarketWatch6 days ago

    Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million

    Pfizer Inc. said Wednesday it has paid 45 million euro, or the equivalent of $51 million to acquire a 15% equity stake in privately held gene therapy company Vivet Therapeutics, and has acquired an option to buy the rest of Vivet shares for EUR560 million ($635.8 million). Pfizer's stock rose 0.2% in premarket trade. Pfizer and Vivet will collaborate on developing VTX-801, Vivet's treatment for Wilson disease, a life-threatening liver disorder of impaired copper transport. Under terms of the deal, Pfizer can exercise its option to buy 100% of Vivet after the company's delivery of certain data from the phase 1/2 trial for VTX-801. Monika Vnuk, vice president of worldwide business development at Pfizer, will join Vivet's board of directors. Pfizer's stock has gained 16.4% over the past 12 months through Tuesday, while the Dow Jones Industrial Average has tacked on 4.7%.

  • Business Wire6 days ago

    Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

    Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease.

  • Morningstar6 days ago

    5 High-Quality, High-Yielding Stocks

    Earlier this week , we looked at the top 10 dividend-yielding stocks among our Ultimate Stock Pickers, a collection of managers whose stock-picking prowess we admire. A subset of the Morningstar US Market Index (which represents 97% of equity market capitalization), this index tracks the top 75 high-yielding stocks that meet our screening requirements for quality and financial health. How are the index constituents chosen?

  • Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
    PR Newswire6 days ago

    Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

    DARMSTADT, Germany and NEW YORK , March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , which operates its biopharmaceutical business as EMD Serono in the US and ...

  • Pfizer (PFE) Gains As Market Dips: What You Should Know
    Zacks6 days ago

    Pfizer (PFE) Gains As Market Dips: What You Should Know

    Pfizer (PFE) closed the most recent trading day at $42.32, moving +1.22% from the previous trading session.

  • Analysts Reduce Pfizer’s Target Price in March
    Market Realist7 days ago

    Analysts Reduce Pfizer’s Target Price in March

    How Major Pharmaceutical Stocks Are Positioned This MonthAnalysts’ recommendations and target price Wall Street analysts expect a potential upside of 5.57% for Pfizer (PFE) based on the company’s closing price on March 18. In 2019, analysts have

  • Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
    Zacks7 days ago

    Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105

    Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.

  • Final Trades: Verizon, XPO, Pfizer, Alphabet and BB&T
    CNBC Videos4 days ago

    Final Trades: Verizon, XPO, Pfizer, Alphabet and BB&T

    The "Halftime Report" traders give their top stocks to watch for the second half.